De Novo device
reSet
Pear Therapeutics, Inc. · Computerized Behavioral Therapy Device For Substance Use Disorders (PWE, Class II) · First FDA decision Sep 14, 2017, newest Sep 14, 2017OCD, PTSD and other psychiatric conditions
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
49
Naming "reSet"
MAUDE reports
0
Brand "reSet", since 2015
PubMed studies
6,834
Mentioning "reSet"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing reSet
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Intensive Behavioral Therapy for ObesityNational analysisReview closedCAG-00423NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational analysisReview closedCAG-00424NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for ObesityNational determinationOn the books210.12Updated Dec 2, 2024
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational determinationOn the books210.11Updated Dec 2, 2024
- Fluidized Therapy Dry Heat for Certain Musculoskeletal DisordersNational determinationOn the books150.8Updated Apr 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "reSet", any status and sponsor, newest update first.
- Vagus Nerve Stimulation for Moderate to Severe Rheumatoid ArthritisPivotal-lookingActive, not recruiting
SetPoint Medical CorporationNot on our public-company list
NCT04539964 · 243 participants · Start Jan 11, 2021 · Primary completion May 16, 2024
Device: Active stimulation; Non-active stimulation · For: Rheumatoid Arthritis
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 43 sites in all
University of MinnesotaAcademic, hospital or other
NCT05897775 · 23 participants (planned) · Start Sep 11, 2023 · Primary completion Jun 30, 2028
Device: Deep brain stimulation · For: Essential Tremor; Upper Extremity Essential Tremor
Sites: Minneapolis, Minnesota
- The RESET System Pivotal Clinical Trial (Protocol Revision K)Pivotal-lookingRecruiting
Morphic Medical Inc.Not on our public-company list
NCT04101669 · 264 participants (planned) · Start Sep 9, 2019 · Primary completion Dec 30, 2027
Device: RESET Liner · For: Diabetes type2; Obesity
Sites: Gilbert, Arizona; Tucson, Arizona; Washington D.C., District of Columbia · 27 sites in all
46 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "reSet", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PWE
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "reSet"[tiab]. The summary above synthesizes these.
- Reset.
Work · 2025
- My weekly reset.
Hibbing P · Science · 2024
- Defining immune reset: achieving sustained remission in autoimmune diseases.
Junt T, Calzascia T, Traggiai E, et al. · Nat Rev Immunol · 2025Review
- Active-reset protein sensors enable continuous in vivo monitoring of inflammation.
Zargartalebi H, Mirzaie S, GhavamiNejad A, et al. · Science · 2024Research Support, Non-U.S. Gov't
- Melanoma Screening-Time for a Reset?
Halpern AC, Marchetti MA · JAMA Dermatol · 2021Editorial, Research Support, N.I.H., Extramural
- Optimally Fast Qubit Reset.
Liu Y, Huang C, Zhang X, et al. · Phys Rev Lett · 2025
- Reset Osmostat: Facts and Controversies.
Feder J, Gomez JM, Serra-Aguirre F, et al. · Indian J Nephrol · 2019
- Endometriosis: Is it Time to Reset the Clock?
Frishman GN · J Minim Invasive Gynecol · 2024Editorial, Comment
- Time to reset our training and certification standards.
Jordan WD · J Vasc Surg · 2024Editorial, Comment
- Biotech financing: divide and reset.
Senior M · Nat Biotechnol · 2025News
- Time to Reset and Recharge.
Davidson HE · Consult Pharm · 2017Editorial, Introductory Journal Article
- [Omicron, a reset in the management of the pandemic].
Simó Miñana J · Aten Primaria · 2022Editorial
Other devices of this type
Also filed under product code PWE.
- reSET-OPear Therapeutics, Inc. · 510(k) 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.